Diefenhardt M, Ludmir EB, Hofheinz HD, et al. -Since, few studies have shown superior clinical outcome in women with melanoma, lymphoma, glioblastoma, sarcoma, lung cancer, gastric cancer, and anal cancer in comparison with males, however, therefore, in this CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 randomized clinical trials of rectal cancer, experts ascertained the relationship of gender with toxic impacts, treatment adherence, and oncologic outcomes. In people with cancer, interest had been rising about the correlation of gender with toxic impacts of treatment and clinical outcome. As exhibited in lung and colon cancer, sarcoma, Hodgkin lymphoma, and glioblastoma, the risk of toxic impacts from chemotherapy was greater in women vs men which could be defined by various pharmacokinetics and pharmacodynamics.